drugset / Trial / NCT06215911

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

NCT06215911 ↗

Phase 2 Completed 557 enrolled Cardurion Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.

Timeline

Start
2024-02-13
Primary completion
2025-10-10
Completion
2025-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tovinontrine Small molecule — Oral

Indications